Artificial intelligence (AI) has had its fits and starts over the years, with the last two featuring a more palpable surge. Shifting from fence-sitting to either FOMO, outside pressure, or internal optimism in the biopharma industry, AI has moved to the question of its actual impact on a company’s valuation. The study examines five subsectors under healthcare—biotechnology, pharmaceuticals, life sciences tools and services, payers and providers, and equipment and supplies. The report mapped out the basic correlation for AI positivity in biotech as a natural symbiosis. Whereas, Serednesky explained, pharma is only getting high marks for AI in valuation when it can contribute to a tangible or reasonable impact on financial performance.